Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4

• Sponsor: Cancer Trials Ireland (Other)
• Overall Status: Terminated
• CT.gov ID: NCT01726309
• Collaborator: (none)
• Enrollment: 161
• Locations: 10
• Actual Duration (Months): 120.3
• Patients Per Site: 16.1
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

Primary Objective:

Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.

Secondary Objectives:

Correlation of SNP profile with indicators of tumour response parameters, such as radiological response, duration of response, time to progression (TTP), overall survival (OS) time, incidence of non-dermatological adverse events.

Condition or Disease	Intervention/Treatment	Phase
Colorectal Cancer; Non-Small Cell Lung Cancer

Detailed Description

Baseline assessment:

• Contact Lenses

• Medical History

• Previous chemotherapy

• Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)

• Symptom Assessment (Pre-existing skin and/or eye conditions, CEA measurement (CRC only), Disease status (TNM Staging))

• Planned chemotherapy regimen

• Radiotherapy

Blood Sample: A 2ml blood sample should be collected in ethylenediamine-tetraacetic acid (EDTA) containing Vacutainer at any time before or after starting treatment. DNA will be extracted from the samples and the 11 SNPs in the region of the EGFR gene encoding domain III will be characterized.

Follow-up Assessment: with every second cycle of Cetuximab- or Panitumumab-containing regimen (CRC: every 2. Week; NSCLC: every 3-4 weeks):

• Visit Number and Date

• Vital Signs (weight, height, Karnofsky Performance status, heart rate, blood pressure)

• Symptom Assessment (CEA measurement (CRC only), Disease status (TMN Staging), Skin Toxicity (CTCAE) grading)

• Current chemotherapy regimen

• Radiotherapy

• CEA measurement only for CRC (every second cycle/every 4 weeks)

Long-term follow-up (up to 5 years):

• CT restaging (TNM Staging) should be done 3 monthly for as long as the subject is receiving Cetuximab- or Panitumumab- containing regimen or if there is suspicion of disease progression.

• OS

Study Design

• Study Type: Observational
• Actual Enrollment: 161 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Correlation of Single Nucleotide Polymorphism (SNP) Profile of Domain III of EGFR to Skin Toxicity and Disease Response to Treatment With Erbitux Requirements
• Actual Study Start Date: May 1, 2011
• Actual Primary Completion Date: May 11, 2021
• Actual Study Completion Date: May 11, 2021

Arms and Interventions

Arm	Intervention/Treatment
Stage IV CRC
Stage IV NSCLC

Outcome Measures

Primary Outcome Measures

1. Correlation between the type and degree of reported skin and/or eye reaction and the SNP profile of the EGFR domain III region. [Throughout treatment with up to 5 years in follow up]

   Using Common Terminology Criteria for Adverse Events (CTCAE) version 4

Secondary Outcome Measures

1. Correlation between the SNP profile(s) and disease response [Throughout treatment with up to 5 years in follow up]

   Time to progression TTP and OS over 5 years

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Stage IV (AJCC 7th Edition TMN Staging, Appendix C), histologically confirmed CRC with wild-type KRAS and not a candidate for metastasectomy.

2. Stage IV (AJCC 7th Edition, TMN Staging, Appendix C) NSCLC expressing EGFR (IHC tested)

3. Patients, who will receive treatment with an EGFR-antibody (Cetuximab or Panitumumab).

4. Karnofsky performance status (Appendix B) score ≥60.

5. Acceptable laboratory values:

• Haemoglobin ≥ 9 g/dL.

• Neutrophil count ≥ 1.0 x 10^9/L.

• Platelet count ≥100 x 10^9/L.

• Serum creatinine ≤1.5 times the upper limit of normal.

• Bilirubin ≤1.5 times the upper limit of normal.

• Aspartate aminotransferase and alanine aminotransferase ≤5 times the upper limit of normal.

Exclusion Criteria:

1. Aged < 18 years

2. Prior exposure to Cetuximab or Panitumumab

3. The CRC does not carry wild-type KRAS.

4. The NSCLC stains negative for EGFR protein expression

5. Second cancer diagnosis (apart from non-melanoma skin cancer)

6. Known hypersensitivity to Cetuximab or Panitumumab, or murine protein.

7. Known history of coronary artery disease, arrhythmias, or congestive heart failure (If the treating physician feels that a patient's coronary artery disease / arrhythmia / congestive heart failure does not place him/her at risk from treatment with an anti-EGFR antibody, the person can be included. This is a clinical decision, which has to be made by the treating physician).

8. Known to be pregnant (pregnancy test is not mandatory) or breast-feeding.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Letterkenny General Hospital	Letterkenny	Donegal	Ireland
2	Bon Secours Hospital	Cork		Ireland
3	Cork University Hospital	Cork		Ireland
4	St Vincent's University Hospital	Dublin		Ireland	4
5	Mater Misericordiae University Hospital	Dublin		Ireland	7
6	Beaumont Hospital	Dublin		Ireland
7	The Adelaide & Meath Hosptal, Dublin Incorporating The National Children's Hospital	Dublin		Ireland
8	Galway University Hospital	Galway		Ireland
9	Our Lady of Lourdes Hospital, Drogheda	Louth		Ireland
10	Waterford Regional Hospital	Waterford		Ireland

Sponsors and Collaborators

• Cancer Trials Ireland

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Cancer Trials Ireland
• ClinicalTrials.gov Identifier: NCT01726309
• Other Study ID Numbers: ICORG 08-40
• First Posted: Nov 14, 2012
• Last Update Posted: Jan 21, 2022
• Last Verified: Jan 1, 2022

• Additional relevant MeSH terms: Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms

Study Results

No Results Posted as of Jan 21, 2022